Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Liabilities and Shareholders Equity (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Liabilities and Shareholders Equity for 14 consecutive years, with $31.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity rose 4.76% year-over-year to $31.5 million, compared with a TTM value of $123.2 million through Sep 2025, up 3.88%, and an annual FY2024 reading of $30.6 million, up 11.75% over the prior year.
  • Liabilities and Shareholders Equity was $31.5 million for Q3 2025 at Sunshine Biopharma, down from $32.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $42.0 million in Q2 2022 and bottomed at $1.8 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $24.1 million, with a median of $29.2 million recorded in 2025.
  • The sharpest move saw Liabilities and Shareholders Equity soared 2818.08% in 2021, then tumbled 32.34% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $2.2 million in 2021, then skyrocketed by 1227.52% to $29.2 million in 2022, then dropped by 6.49% to $27.3 million in 2023, then rose by 11.75% to $30.6 million in 2024, then grew by 3.03% to $31.5 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for SBFM at $31.5 million in Q3 2025, $32.0 million in Q2 2025, and $29.2 million in Q1 2025.